Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Hubers SA, Brown NJ (2016) Circulation 133: 1115-24 Response by Hubers and Brown to Letter Regarding Article, "Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition". Hubers SA, Brown NJ (2016) Circulation 134: e11-2 Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. Holtkamp FA, de Zeeuw D, de Graeff PA, Laverman GD, Berl T, Remuzzi G, Packham D, Lewis JB, Parving HH, Lambers Heerspink HJ (2011) Eur Heart J 32: 1493-9 Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. Cheng HF, Wang JL, Zhang MZ, Miyazaki Y, Ichikawa I, McKanna JA, Harris RC (1999) J Clin Invest 103: 953-61 Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis. Gamboa JL, Pretorius M, Todd-Tzanetos DR, Luther JM, Yu C, Ikizler TA, Brown NJ (2012) J Am Soc Nephrol 23: 334-42 Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Tanaka R, Kon V, Yoshioka T, Ichikawa I, Fogo A (1994) Kidney Int 45: 537-43 Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Ma LJ, Nakamura S, Whitsitt JS, Marcantoni C, Davidson JM, Fogo AB (2000) Kidney Int 58: 2425-36 Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A (1992) Kidney Int 42: 46-55 Internephron heterogeneity of growth factors and sclerosis--modulation of platelet-derived growth factor by angiotensin II. Tanaka R, Sugihara K, Tatematsu A, Fogo A (1995) Kidney Int 47: 131-9 Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kon V, Fogo A, Ichikawa I (1993) Kidney Int 44: 545-50 Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A (1997) Kidney Int 51: 164-72 ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Brown NJ, Kumar S, Painter CA, Vaughan DE (2002) Hypertension 40: 859-65 Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Brown NJ, Agirbasli M, Vaughan DE (1999) Hypertension 34: 285-90 Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1. Sawathiparnich P, Murphey LJ, Kumar S, Vaughan DE, Brown NJ (2003) J Clin Endocrinol Metab 88: 3867-73 The molecular basis of increased glomerulosclerosis after blockade of the renin angiotensin system in growth hormone transgenic mice. Peten EP, Striker LJ, Fogo A, Ichikawa I, Patel A, Striker GE (1994) Mol Med 1: 104-15 Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. Yamamoto S, Zhong J, Yancey PG, Zuo Y, Linton MF, Fazio S, Yang H, Narita I, Kon V (2015) Atherosclerosis 242: 56-64 Potential side effects of renin inhibitors--mechanisms based on comparison with other renin-angiotensin blockers. Cheng H, Harris RC (2006) Expert Opin Drug Saf 5: 631-41
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.